https://www.selleckchem.com/pr....oducts/wnt-c59-c59.h
The difference between the groups was not statistically significant (P= 0.3). The median OS was 33 months in all patients. In subgroup analysis, the median OS was 39 and 27.9months in PTR (+) and PTR (-) patients, respectively. The difference between the groups was statistically significant (P= 0.002). After adjusting for confounding factors, PTR and ECOG performance score were the independent prognostic factors for OS. PTR improved the OS in patients with RAS wild-type synchronous left-sided colon or rectum cancer treated with cetu
Like
Comment
Share
